Equivalent Oral Divalproex Dose
When converting from intravenous valproic acid 500 mg three times daily (1500 mg/day total) to oral divalproex sodium, use the same total daily dose of 1500 mg/day divided into 2-3 doses (e.g., 500 mg three times daily or 750 mg twice daily). 1, 2
Conversion Rationale
The conversion is straightforward because equivalent oral doses of divalproex sodium and valproic acid deliver equivalent quantities of valproate ion systemically 1, 2. Both formulations dissociate to the valproate ion—the active moiety—in the gastrointestinal tract, making them bioequivalent on a milligram-per-milligram basis.
Key Pharmacokinetic Principles
- Bioequivalence: Oral divalproex sodium and IV valproic acid provide the same systemic exposure when given at identical total daily doses 1, 2
- Absorption differences are clinically insignificant: While the rate of absorption (Tmax) varies between formulations—delayed-release divalproex tablets have a Tmax of 4-8 hours versus immediate absorption with IV—these differences are inconsequential under steady-state conditions achieved in chronic use 1, 2
- Total daily bioavailability determines efficacy: Studies in epilepsy models demonstrate that total daily systemic bioavailability, not peak-to-trough ratios, is the primary determinant of seizure control 1, 2
Practical Conversion Strategy
Timing Considerations
When switching from IV to oral divalproex:
- For delayed-release divalproex: Initiate within 2 hours of the last IV dose to prevent subtherapeutic levels during the delayed absorption phase 3
- For extended-release divalproex: Can be initiated concurrently with discontinuation of IV therapy 3
The rapid decline in plasma valproate concentrations after stopping IV administration, combined with delayed initial absorption from delayed-release formulations, necessitates early initiation of oral therapy 3.
Dosing Schedule
- Delayed-release divalproex: 500 mg three times daily (maintains your current TID schedule) or 750 mg twice daily
- Extended-release divalproex: 1500 mg once daily (if available and appropriate for the indication)
Monitoring Requirements
Close monitoring of clinical status and valproate plasma concentrations is essential during any formulation change 1, 2. The therapeutic range is typically 50-100 mcg/mL for epilepsy and 50-125 mcg/mL for mania 2.
Important Caveats
- Protein binding is concentration-dependent: Free fraction increases from 10% at 40 mcg/mL to 18.5% at 130 mcg/mL, affecting clearance 1, 2
- Patient-specific factors: Elderly patients, those with hepatic/renal disease, and those on interacting medications (e.g., aspirin) may have altered pharmacokinetics requiring dose adjustment 1, 2
- Concomitant medications: Any addition or discontinuation of other drugs should prompt reassessment of valproate levels 1, 2